Angele Kelder

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.

Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.